enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of “Buy” from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $25.89.

Several analysts have recently weighed in on ENGN shares. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. Citizens Jmp raised enGene to a “strong-buy” rating in a report on Monday, November 18th. Piper Sandler started coverage on enGene in a research note on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price objective on the stock. UBS Group cut enGene from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Finally, Raymond James started coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target for the company.

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $5.75 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The business’s fifty day moving average price is $6.75 and its two-hundred day moving average price is $7.17. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The stock has a market capitalization of $254.42 million, a price-to-earnings ratio of -9.92 and a beta of -0.65.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, analysts predict that enGene will post -1.56 EPS for the current fiscal year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wolverine Asset Management LLC bought a new position in shares of enGene in the 3rd quarter valued at about $37,000. Vontobel Holding Ltd. bought a new stake in shares of enGene during the fourth quarter worth approximately $69,000. Jane Street Group LLC acquired a new position in enGene in the fourth quarter valued at approximately $93,000. Toronto Dominion Bank bought a new position in enGene in the fourth quarter valued at approximately $97,000. Finally, Cubist Systematic Strategies LLC grew its holdings in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after acquiring an additional 2,080 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.